Past, present and future of primary systemic treatment in breast cancer

Table 1 Chemotherapy schemes used in neoadjuvant treatment, with category-1 evidence and that can be used in neoadjuvant treatment

Ref.		Chemotherapy scheme	Drugs/dose
Martin et al[70]		CAT	Docetaxel 75 mg/m2iv on day 1
			Doxorubicin 50 mg/m2iv on day 1
			Cyclophosphamide 500 mg/m2iv on day 1
			Cycled every 21 d for 6 cycles (all cycles are with filgrastim support)
Citron et al[71]	Non-trastuzumab containing regimens	Dose-dense AC followed by paclitaxel every 2 wk	Doxorubicin 60 mg/m2iv on day 1
			Cyclophosphamide 600 mg/m2iv on day 1
			Cycled every 14 d for 4 cycles
			Followed by paclitaxel 175 mg/m2 as a 3 h iv infusion on day 1
			Cycled every 14 d for 4 cycles (all cycles are with filgrastim support)
Henderson et al[72]		AC followed by weekly paclitaxel	Doxorubicin 60 mg/m2 on day 1
			Cyclophosphamide 600 mg/m2iv on day 1
			Cycled every 21 d for 4 cycles
			Followed by paclitaxel 80 mg/m2 as a 1 h iv infusion weekly from day 1 for 12 wk
Jones et al[73]		CT	Docetaxel 75 mg/m2 on day 1
			Cyclophosphamide 600 mg/m2iv on day 1
			Cycled every 21 d for 4 cycles
			(all cycles are with filgrastim support)
Romond et al[74]	Trastuzumab containing regimens	AC followed by weekly paclitaxel concurrent with trastuzumab	Doxorubicin 60 mg/m2iv on day 1
			Cyclophosphamide 600 mg/m2iv on day 1
			Cycled every 21 d for 4 cycles
			Followed by Paclitaxel 80 mg/m2 as a 1 h iv weekly for 12 wk
			With Trastuzumab 4 mg/kg iv with first dose of paclitaxel
			Followed by Trastuzumab 2 mg/kg iv weekly to complete 1 yr of treatment
			Cardiac monitoring at baseline, 3, 6, and 9 mo
Robert et al[75]		TCH	Docetaxel 75 mg/m2iv day 1
			Carboplatin AUC 6 iv on day 1
			Cycled every 21 d for 6 cycles
			With Trastuzumab 4 mg/kg in week 1
			Followed by Trastuzumab 2 mg/kg for 17 wk
			Followed by Trastuzumab 6 mg/kg iv every 3 wk to complete 1 yr of trastuzumab therapy
			Cardiac monitoring at baseline, at 3, 6, and 9 mo

CAT: Docetaxel, doxorubicin and cyclophosfamide; AC: Doxorubicin plus cyclophosfamide; CT: Docetaxel plus cyclophosfamide; TCH: Docetaxel, cyclophosfamide plus trastuzumab.